A Global Leader in Class Action Protection

Jeffrey L. Kodroff

Jeffrey L. Kodroff
Jeffrey L. Kodroff
Philadelphia, Pennsylvania
phone (215) 496-0300
fax (215) 496-6611
email Email Me

Jeffrey Kodroff, firm partner, concentrates his practice in complex antitrust, healthcare and consumer litigation. He was among the first attorneys to represent clients in litigation against national health maintenance organizations (HMOs). As reported in the December 10, 2001 issue of the National Law Journal, Mr. Kodroff developed and filed the first private lawsuit against the pharmaceutical industry for its illegal marketing practices and use of the published average wholesale price which causes consumers, health and welfare funds and insurance companies to drastically overpay for certain drugs. The original case was against TAP Pharmaceutical, the manufacturer of the cancer drug Lupron, and Mr. Kodroff, as Lead Counsel, was instrumental in obtaining a $150 million recovery. See In re: Lupron Marketing and Sales Practices Litigation (MDL No. 1430).

He has also served as lead or co-lead counsel in other substantial pharmaceutical marketing cases, including New England Carpenters Health Benefits Fund v. First Databank, Inc. and McKesson Corp., C.A. 05-11148 (D. Mass.); and District 37 Health and Securities Fund v. Medi-Span, C.A. No. 07-10988 (D. Mass. 2007). This massive class action litigation was against pharmaceutical wholesaling giant McKesson Corporation (“McKesson”) and pharmaceutical pricing publishers First DataBank, Inc. (“FDB”) and Medi-Span. The case addressed an unlawful 5% mark-up in the Average Wholesale Prices (“AWPs”) of various drugs, causing consumers and third party payors to overpay for pharmaceuticals. The case settled for $350 million plus an agreement to roll back AWPs by 5%, thereby saving the Class and others hundreds of millions of dollars. Mr. Kodroff has also been very active in litigation against brand named pharmaceutical companies in their attempts to keep generic drugs from entering the market. As one of Co-Lead Counsel he was able to recover $150 million from GSK in a patent litigation relating to the drug Paxil. To date, he has helped recover hundreds of millions of dollars of overpayment for pharmaceutical drugs.

Mr. Kodroff has served as a Continuing Legal Education presenter on class actions and health care issues as well as making presentations at the NCPERS Health Care Symposium and the Pennsylvania Public Employees Retirement System Conference.

He also serves on the advisory board for the Bureau of National Affairs Class Action Litigation Report. Mr. Kodroff also appeared with one of his clients before the U.S. House of Representatives, Subcommittee on Housing and Community Opportunity, Committee on Banking and Financial Services on the issue of predatory lending.

Mr. Kodroff is admitted to practice in the Commonwealth of Pennsylvania and the United States District Courts for the Middle and Eastern Districts of Pennsylvania. He is a member of the Pennsylvania, Philadelphia and American Bar Associations. He also serves on the advisory board for the Bureau of National Affairs Class Action Litigation Report.

A graduate of LaSalle University, where he earned his undergraduate degree in finance (magna cum laude, 1986), Mr. Kodroff received his law degree from Temple University School of Law (1989). He is a resident of Dresher, Pennsylvania. Mr. Kodroff is AV-rated by Martindale-Hubbell.

Areas of Practice:
Complex Antitrust
Securities and Consumer Litigation
Bar Admissions:
Pennsylvania, 1989
U.S. District Court Middle District of Pennsylvania
U.S. District Court Eastern District of Pennsylvania
U.S. Federal Courts, 1989
Temple University School of Law, Philadelphia, Pennsylvania, 1989
La Salle University, Philadelphia, Pennsylvania, 1986
Honors: Magna Cum Laude
Major: Finance
Professional Associations and Memberships:
Pennsylvania Bar Association
Philadelphia Bar Association
American Bar Association
Bureau of National Affairs Class Action Litigation Report
Member, Advisory Board